Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin ...

Metsera, Inc. (NASDAQ:MTSR) is one of the 11 Hot New Stocks to Invest in Now. On June 22, Metsera, Inc. (NASDAQ:MTSR) presented at the 85th Scientific Sessions of the American Diabetes Association ...

Metsera is developing the combination of MET-233i and MET-097i via the FDA biologic pathway with the intent to pursue the combination’s regulatory approval in the United States under a BLA.

Metsera said the treatment has a half life of about 16 days. The current GLP-1 drugs on the market, such as Wegovy and Zepbound, are dosed weekly, so a monthly option could be more convenient and ...

Metsera will present significant clinical data from its Phase 1/2 trial of MET-097i, a next-generation GLP-1 receptor agonist, at a prominent scientific conference, enhancing the company's ...

--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its ...

We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a look at where Metsera (NASDAQ:MTSR) stands against other stocks ...

View Metsera, Inc. MTSR stock quote prices, financial information, real-time forecasts, and company news from CNN.

Metsera has $187.6 million of cash and cash equivalents, according to the filings. Its offering was led by Bank of America Corp., Goldman Sachs Group Inc., Evercore Inc., Guggenheim Securities ...

Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

Metsera will present clinical data from MET-097i’s Phase 1/2 clinical trial in two presentations, including change in body weight and tolerability data after twelve weekly doses and after a ...